Compare Solstice Advanced Materials Inc. Common Stock (SOLS) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Solstice Advanced Materials Inc. Common Stock vs Twist Bioscience Corp — how do they compare? Solstice Advanced Materials Inc. Common Stock trades at $59.92 (market cap $9.55B), while Twist Bioscience Corp trades at $144 (market cap $9.82B). The key difference: Solstice Advanced Materials Inc. Common Stock and Twist Bioscience Corp are close in size by market cap, and Solstice Advanced Materials Inc. Common Stock pays a 0.5% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Solstice Advanced Materials Inc. Common Stock for 0 Days and Twist Bioscience Corp for 27 Days on average.
| SOLS | TWST | |
|---|---|---|
Market Cap | $9.55B | $9.82B |
Volume | 2,661,277 | 2,115,226 |
Sector | Basic Materials | Health |
52-Week High | $88.60 | $205.00 |
52-Week Low | $41.43 | $25.45 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $11.23B | $9.75B |
Dividend Yield | 0.5% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Solstice Advanced Materials (SOLS) trades at $60.91, up 0.33% with neutral technical signals. The company shows strong profitability with 30.64% gross margins and 14.95% ROE, though Q4 2025 earnings missed expectations. Recent developments include a $49M R&D expansion and termination of the Element Solutions merger, with the board authorizing a $500M share repurchase program. Analyst consensus is bullish with 80% buy ratings and a $80.22 price target representing 32% upside potential.
SOLS presents a compelling growth story with consistent earnings beats and institutional accumulation, though elevated P/E of 46.07 warrants caution. Key risks include execution challenges post-merger termination and margin pressure as profit margins declined from 6.09% to 5.12% year-over-year. The stock offers substantial upside if management delivers on growth initiatives while maintaining current profitability levels.
Twist Bioscience (TWST) trades at $151.33, down 0.35% on the day, with a bullish technical signal but negative profitability. Revenue growth is strong, increasing from $204M in 2022 to $377M in 2025, yet net losses persist. Recent news highlights a partnership with Eli Lilly's TuneLab AI platform, boosting investor optimism. The stock is near its consensus price target of $153.70, with institutional buying noted in Q2 2026.
Outlook remains speculative; growth prospects from AI-driven drug discovery are promising, but profitability challenges and cash burn pose significant risks. Analyst consensus is bullish (73% buy ratings), yet high valuation multiples and consistent earnings misses warrant caution for investors seeking near-term returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Solstice Advanced Materials Inc. Common Stock
Solstice Advanced Materials Inc. is a specialty materials company spun off from Honeywell in 2025, producing low-global-warming-potential refrigerants, blowing agents, and industrial solvents through its Refrigerants and Applied Solutions segment. Its Electronic and Specialty Materials segment supplies semiconductor materials, high-strength fibers, and healthcare-packaging films.
Read more on SOLS →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
